Methods of treating multiple sclerosis using STRO-1+ and TNAP+ multipotential cells
View Patent ↗The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom.
1. A method for treating a subject with multiple sclerosis, the method comprising administering to the subject a population of cells enriched for STRO-1 + TNAP + multipotential cells in an amount effective to treat the subject.
2. The method of claim 1 , wherein the multiple sclerosis is associated with, or caused by, a T cell response to an inflammatory stimulus.
3. The method of claim 1 , wherein the multiple sclerosis is a chronic progressive form of multiple sclerosis or a relapsing-remitting form of multiple sclerosis.
4. The method of claim 1 , wherein the population enriched for STRO-1 + TNAP + multipotential cells is administered systemically.
5. The method of claim 1 , comprising:
(i) administering an amount of the population enriched for STRO-1 + TNAP + multipotential cells effective to increase the number of regulatory T (Treg) cells in the subject and/or at the site of pathogenesis of the disease;
(ii) administering between 2×10 6 and 8×10 6 STRO-1 + TNAP + multipotential cells per kg;
(iii) administering between 3×10 6 and 6×10 6 STRO-1 + TNAP + multipotential cells per kg; or
(iv) administering a low dose of STRO-1 + TNAP + multipotential cells,
wherein the low dose of STRO-1 + TNAP + cells comprises between 0.1×10 6 and 3×10 6 STRO-1 + cells per kg or comprises about 3×10 6 STRO-1 + TNAP + cells.
6. The method of claim 1 , wherein the population enriched for STRO-1 + TNAP + multipotential cells is administered once weekly or is administered once every four weeks.
7. The method of claim 1 , wherein the population enriched for STRO-1 + TNAP + multipotential cells is autogeneic or allogeneic.
8. The method of claim 1 , wherein the population enriched for STRO-1 + TNAP + multipotential cells has been culture expanded prior to administration.
9. A method for treating a subject with multiple sclerosis, the method comprising administering to the subject a population of cells enriched for STRO-1 + TNAP + multipotential cells such that at least 5% of the cells are STRO-1 + TNAP + multipotential cells so as to treat the subject.